1.
Nat Med
; 29(6): 1298-1301, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37280276
2.
Urologe A
; 52(4): 576-9, 2013 Apr.
Artigo
em Alemão
| MEDLINE
| ID: mdl-23571802
RESUMO
The PREFERE study is a multicenter randomized study of patients with low or early intermediate risk for prostatic cancer. The four treatment options, radical prostatectomy, percutaneous irradiation therapy, permanent seed implantation and active surveillance recommended by the German S3 guidelines and international guidelines will be tested and compared with respect to effectiveness and potential side effects. Over a period of 4 years a total of 7,600 patients are to be recruited and assigned to 1 of these 4 therapy forms according to personal preference (by possible exclusion of 1 or 2 therapy options) in a 2-4 arm study design by randomization.